CytoSorbents Corp: Update on Nasdaq Listing Status

If you track CytoSorbents (ticker: CTSO), you may have seen a recent filing regarding their Nasdaq listing. If you are wondering what this means for your portfolio, here is the breakdown in plain English.

1. What happened?

Nasdaq granted CytoSorbents a 180-day extension to meet its minimum price rules. The stock currently trades below $1.00, which risks a delisting from the Nasdaq Capital Market. To stay listed, the stock must close at or above $1.00 for at least 10 consecutive business days before the deadline.

2. The Timeline

The company received notice of this second 180-day extension on April 1, 2026. They now have until September 28, 2026, to meet the requirement.

3. Why does this matter?

This is a "yellow flag" for investors. A Nasdaq listing offers credibility and makes it easier to trade the stock. If delisted, the stock moves to "over-the-counter" (OTC) markets. These markets generally have lower trading volume and wider price gaps between buyers and sellers, and many institutional investors are restricted from trading on them.

4. The "Reverse Split" Possibility

The company is considering a "reverse stock split" to meet the rules. For example, in a 1-for-10 split, if you own 1,000 shares at $0.40 ($400 total), you would then own 100 shares at $4.00 ($400 total). This does not change the company's total market value, but it artificially boosts the share price to meet listing standards. The company hasn't provided specific details on if or when they will trigger this, but it remains a primary tool to avoid delisting.

5. Who is affected?

• Investors: Shareholders may see more price volatility as the September 28 deadline nears. If the price does not rise naturally, the board might choose a reverse split, which the market sometimes views as a sign of financial pressure.
• The Company: CytoSorbents relies on its Nasdaq listing to maintain access to capital markets. As a medical device firm, it needs to fund ongoing research and the commercialization of its CytoSorb blood purification technology.

6. What should you do?

• Don't panic: This is a technical rule regarding share price, not necessarily a reflection of the company’s core technology or its ability to sell products.
• Watch for news: Keep an eye on future SEC filings for any official announcements regarding a reverse split or other compliance measures.
• Focus on the business: The company reported approximately $40 million in revenue for 2025. Monitor upcoming earnings reports to see if the company is growing and moving toward profitability. Ultimately, long-term stock performance is driven by business results, not technical listing fixes.

Disclaimer: I am an AI, not a financial advisor. Stock trading involves risk. Always do your own research and consider your personal financial situation before making any investment decisions.